A Phase 3 interventional study of CBD-OS and Placebo in Developmental and Epileptic Encephalopathy (DEE), sponsored by Jazz Pharmaceuticals. Not yet recruiting. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-07-24.
Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The efficacy, safety, and tolerability of CBD-OS have been evaluated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous sclerosis complex (TSC). The current JZP926-303 study is being conducted to evaluate the safety and efficacy of CBD-OS in participants with Developmental and Epileptic Encephalopathy (DEE).
This Phase 3, multicenter, randomized, placebo-controlled, double-blind study will evaluate the efficacy and safety of CBD-OS in participants aged ≥ 1 year with DEE. The primary objective of the 6-week Double-blind Treatment Period of the study is to assess the efficacy of CBD-OS in reducing the frequency of countable motor seizures compared with placebo in participants with DEE. In addition, the Double-Blind Treatment Period will also assess the safety and tolerability of CBD-OS. The optional 6-month open-label extension (OLE) will provide additional data on the long-term efficacy, safety, and tolerability of CBD-OS.
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Counted across the registry records on this site, refreshed daily.
Participants are eligible to be included in the study only if all the following criteria apply:
Participants are excluded from the study if any of the following criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with DEE will be randomized to CBD-OS up to 10 mg/kg twice daily for a 6-week treatment period.
Drug: CBD-OS
Participants with DEE will be randomized to matching placebo for a 6-week treatment period.
Drug: Placebo
Participants with DEE who completed the double-blind phase of the study and enter the optional OLE will begin a 22-week open-label treatment period with CBD-OS up to 10 mg/kg twice daily following a 2-week Blinded Transition Period.
Drug: CBD-OS
Oral solution, twice daily
Also known as: JZP926-OS
Oral solution, twice daily
Change in Countable Motor Seizure Frequency Per 28 Days
Time frame: Baseline up to 6 weeks of double-blind treatment period
Change in Total Seizure Frequency Per 28 Days
Time frame: Baseline up to 6 weeks of double-blind treatment period
Proportion of Participants Who Achieve ≥ 50% Reduction From Baseline in Countable Motor Seizure Frequency
Time frame: Baseline up to 6 weeks of double-blind treatment period
Caregiver Global Impression of Change (CaGI-C) Score
Time frame: Week 6 of double-blind treatment period
Change from Baseline in Caregiver Global Impression of Severity (CaGI-S) Score
Time frame: Week 6 of double-blind treatment period
Change From Baseline in Number of Countable Motor Seizure-free Days per 28 Days
Time frame: Baseline up to 6 weeks of double-blind treatment period
Clinical Global Impression of Change (CGI-C) Score
Time frame: Week 6 of double-blind treatment period
Change from Baseline in Clinical Global Impression of Severity (CGI-S) Score
Time frame: Week 6 of double-blind treatment period
Number of Participants Reporting Treatment-emergent Adverse Events
Time frame: Baseline up to 6 weeks of double-blind treatment period
Mean Plasma Concentration of CBD
Time frame: Baseline up to 6 weeks of double-blind treatment period
Mean Plasma Concentration of Metabolite 7-OH-CBD
Time frame: Baseline up to 6 weeks of double-blind treatment period
Mean Plasma Concentration of Metabolite 7-COOH-CBD
Time frame: Baseline up to 6 weeks of double-blind treatment period
No study locations are listed for this record.
Plan to share: Yes — In accordance with ICMJE requirements, Jazz Pharmaceuticals may provide qualified external researchers access to individual participant data (IPD) and clinical trial data that underlie the results of this trial upon request. Qualified researchers can submit a request on https://www.jazzpharma.com/science/clinical-trial-data-sharing/ as outlined. Jazz Pharmaceuticals reserves the right not to consider a request. For inquiries about Jazz's data sharing policy contact clinicaldatasharing@jazzpharma.com.
Data sharing details ↗ · www.jazzpharma.com
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Sep 2029, 34 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cannabidiol